Current State of the Art of Micro Air Vehicles

By Alan Kendrick J.D., Nerac Analyst
Originally Published: September 22nd, 2014
Micro Air Vehicles (MAV) and Micro Flyers are a class of unmanned air vehicles that are extremely small and by necessity, extremely maneuverable. These devices are on the order of 20 cm in size weighing less than 100 grams; about the size of a small bird or larger flying insects. The demonstrated and proposed uses for these MAV are numerous and span both military and civilian applications.

Laboratory-Developed Test Regulations

By Roz Sweeney, Ph.D., Nerac Analyst,
Originally Published: September 19th, 2014
Will Laboratory-developed tests (LDTs) require FDA marketing approval?

Laboratory-developed tests (LDTs) are in vitro diagnostic tests typically used within a single-institution’s CLIA lab. The FDA exempted clinical laboratories from registration and listing of tests almost 40 years ago; however, this exemption may no longer apply if the FDA’s new guidance document is implemented. In this guidance document, Framework for Regulatory Oversight of LDTs (July 31, 2014), the FDA proposes regulating LDTs in a similar manner to how it currently regulates IVD manufacturers.

The Young and the Restless: Scientists & Engineers Connecting across Disciplines

By Ben Bahavar Ph.D., Nerac Analyst,
Originally Published: September 15th, 2014.
A recent webinar announcement by the American Chemical Society (ACS) brought attention to a grassroots endeavor by the Network of Early-Career Sustainable Scientist and Engineers (NESSE) and how they are working to build a community of confident and able early-career sustainable scientists. These professionals are said to be connecting across disciplines, sharing knowledge and resources, forging collaborations, and finding solutions towards making research and its outcomes greener and more sustainable. The webinar was presented on September 4, 2014 – the slide deck can be downloaded via this link: Planting the Seeds for Sustainable Chemistry.

An Entirely New Class of Polymers

By Skye McClain, Ph.D., Nerac Analyst,
Originally Published: September 12th, 2014
One news feed I review regularly is at the Kurzweil Accelerating Intellegence website. Ray Kurzweil is the director of engineering at Google, and his website tracks “key breakthroughs in science and technology”. This news source is often one of the first places I find mention of cutting edge research.

Updating Technical Files – Is Your Company Ready for a Notified Body Audit?

by Ron Sills, M.S., Nerac Analyst
Originally published September 10, 2014

Join Nerac analyst Ron Sills in this free, interactive webinar providing an overview of how to create and maintain a Technical File that is compliant and ready for a Notified Body audit; from best practices in document choice and preparation to understanding the critical pieces of your Technical File update.

Ebola: Do we need to worry?

By Rebecca Ryznar, Ph.D., Nerac Associate Analyst
Originally published Sept. 2, 2014

Zaire Ebola virus (EBOV), the particular Ebola viral strain currently spreading across West Africa, causes the most virulent hemorrhagic fever known to man, and kills up to 90% of those infected. Ebola sets the immune system in overdrive and perturbs clotting mechanisms, causing a victim to bleed to death within an average of a week after contracting the virus.

This article examines the threat and takes a look at some of the drugs in development for this deadly virus.

Developing an Innovation Process that Works

By Emma Palmacci Ph.D., VP, Research Services, Nerac Analyst and Louis Donne, Director – Research, Group 4.
Originally published Aug. 26, 2014

Innovation can “just happen,” serendipity can birth an innovative idea. However, great innovators have developed processes to make innovation routine rather than accidental. Companies have shown the value of establishing an innovation management practice which combines internal and external ideas, as well as internal and external paths to market.

A wide-range of different innovation sources are available to companies that want to increase the competitive advantage of their products, each source with its own compromise of strengths and weakness. Group 4 and Nerac have collaborated on an approach that integrates several sources in such a way that the strengths of each are additive while the weaknesses are cancelled out.

In this article, Nerac and Group 4 explore best practices on how to improve a company’s chances of success in innovating new, novel products for the market through technology scouting.

The Ice Bucket Challenge and Funding of ALS Biomedical Research: A Drop in the Bucket

By John Leavitt, Ph.D., Nerac Analyst and Stephen Buxser, Ph.D., Nerac Analyst
Originally published August 21, 2014

For the past week we have seen a lot of giddy newscasters drench themselves with ice water eliciting cries of delight and laughter among their colleagues. Raising $31.5 million for ALS research is nothing to shake a stick at and this effort should be encouraged. But curing a complex, not well understood neurological disease like ALS (amyotrophic lateral sclerosis) will take decades of advanced research and new technological developments that haven’t happened yet.

This post goes behind the scenes of the “Ice Bucket Challenge” and explores the true challenges of bio-medical research funding.